Gain Therapeutics (NASDAQ:GANX) is a biotechnology firm at the forefront of developing therapies for rare genetic diseases and neurodegenerative disorders. The company is pioneering a distinctive drug discovery platform that identifies and develops small molecule therapeutics designed to fix protein misfolding, a common pathological mechanism across its target diseases. Gain's pipeline is focused on addressing unmet medical needs in conditions such as Parkinson's disease, Gaucher disease, and GM1 gangliosidosis, aiming to halt or reverse the progress of these debilitating diseases. With a commitment to innovation and improving patient outcomes, Gain Therapeutics is dedicated to becoming a key player in the field of precision medicine, pushing the boundaries of science to deliver transformative treatments.